APA (7th ed.) Citation

R, T., K, T., G, S., M, T., H, A., T, S., . . . T, S. (2026). Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting. Lung cancer (Amsterdam, Netherlands), 214, 109309. https://doi.org/10.1016/j.lungcan.2026.109309

Chicago Style (17th ed.) Citation

R, Tsugitomi, et al. "Efficacy and Safety of First-line Lenvatinib in Patients with Advanced or Recurrent Thymic Carcinoma in the Real-world Setting." Lung Cancer (Amsterdam, Netherlands) 214 (2026): 109309. https://doi.org/10.1016/j.lungcan.2026.109309.

MLA (9th ed.) Citation

R, Tsugitomi, et al. "Efficacy and Safety of First-line Lenvatinib in Patients with Advanced or Recurrent Thymic Carcinoma in the Real-world Setting." Lung Cancer (Amsterdam, Netherlands), vol. 214, 2026, p. 109309, https://doi.org/10.1016/j.lungcan.2026.109309.